<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Protagonist Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/protagonist-therapeutics-inc</link>
<description>Latest news and press releases for Protagonist Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 17:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/protagonist-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b22178dffbe2df111ba4.webp</url>
<title>Protagonist Therapeutics Inc</title>
<link>https://6ix.com/company/protagonist-therapeutics-inc</link>
</image>
<item>
<title>Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight</title>
<link>https://6ix.com/company/protagonist-therapeutics-inc/news/polycythemia-vera-market-set-for-transformation-key-9-companies-expected-to-enter-by-2036-or-delveinsight</link>
<guid isPermaLink="true">https://6ix.com/company/protagonist-therapeutics-inc/news/polycythemia-vera-market-set-for-transformation-key-9-companies-expected-to-enter-by-2036-or-delveinsight</guid>
<pubDate>Wed, 22 Apr 2026 17:00:00 GMT</pubDate>
<description>The polycythemia vera market is set for expansion by 2036, as new entrants such as Protagonist Therapeutics and Takeda Pharmaceuticals (rusfertide), Merck (bomedemstat), Italfarmaco (givinostat), Ionis Pharmaceuticals and Ono Pharmaceutical (sapablursen), Silence Therapeutics (Divesiran (SLN124)), Perseus Proteomics (PPMX-T003), Disc Medicines (DISC-3405), and others are evaluating their lead candidates in different stages of clinical development, respectively.New York, USA, April 22, 2026 (GLOB</description>
</item>
<item>
<title>Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting</title>
<link>https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-announces-presentation-of-one-year-phase-3-data-for-icotydetm-in-moderate-to-severe-plaque-psoriasis-at-the-2026-american-academy-of-dermatology-aad-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-announces-presentation-of-one-year-phase-3-data-for-icotydetm-in-moderate-to-severe-plaque-psoriasis-at-the-2026-american-academy-of-dermatology-aad-annual-meeting</guid>
<pubDate>Sat, 28 Mar 2026 04:00:00 GMT</pubDate>
<description>One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for</description>
</item>
<item>
<title>Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis </title>
<link>https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-therapeutics-announces-us-fda-approval-of-icotydetm-icotrokinra-for-the-treatment-of-moderate-to-severe-plaque-psoriasis</link>
<guid isPermaLink="true">https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-therapeutics-announces-us-fda-approval-of-icotydetm-icotrokinra-for-the-treatment-of-moderate-to-severe-plaque-psoriasis</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pillApproval</description>
</item>
<item>
<title>Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera</title>
<link>https://6ix.com/company/protagonist-therapeutics-inc/news/takeda-and-protagonist-announce-us-food-and-drug-administration-accepts-new-drug-application-and-grants-priority-review-for-rusfertide-as-a-potential-first-in-class-therapy-for-polycythemia-vera</link>
<guid isPermaLink="true">https://6ix.com/company/protagonist-therapeutics-inc/news/takeda-and-protagonist-announce-us-food-and-drug-administration-accepts-new-drug-application-and-grants-priority-review-for-rusfertide-as-a-potential-first-in-class-therapy-for-polycythemia-vera</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia</description>
</item>
<item>
<title>CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/protagonist-therapeutics-inc/news/correction-protagonist-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/protagonist-therapeutics-inc/news/correction-protagonist-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Wed, 25 Feb 2026 22:15:00 GMT</pubDate>
<description>(This release updates the release that posted earlier on February 25, 2026 to update the sub headlines.) NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year Company expects to opt-out ...</description>
</item>
<item>
<title>Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Wed, 25 Feb 2026 21:05:00 GMT</pubDate>
<description>NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year Company expects to opt-out of the 50:50 profit and loss sharing arrangement for rusfertide with Takeda during a 90-day window expected ...</description>
</item>
<item>
<title>Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026</title>
<link>https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-therapeutics-to-participate-in-multiple-investment-bank-conferences-in-march-2026</link>
<guid isPermaLink="true">https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-therapeutics-to-participate-in-multiple-investment-bank-conferences-in-march-2026</guid>
<pubDate>Tue, 24 Feb 2026 12:30:00 GMT</pubDate>
<description>NEWARK, CA / ACCESS Newswire / February 24, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in multiple investment bank conferences ...</description>
</item>
<item>
<title>Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026</title>
<link>https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-therapeutics-participate-44th-annual-123000806</link>
<guid isPermaLink="true">https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-therapeutics-participate-44th-annual-123000806</guid>
<pubDate>Wed, 07 Jan 2026 12:30:00 GMT</pubDate>
<description>NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the 44th Annual ...</description>
</item>
<item>
<title>Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)</title>
<link>https://6ix.com/company/protagonist-therapeutics-inc/news/takeda-and-protagonist-announce-submission-new-drug-application-nda-rusfertide</link>
<guid isPermaLink="true">https://6ix.com/company/protagonist-therapeutics-inc/news/takeda-and-protagonist-announce-submission-new-drug-application-nda-rusfertide</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes</description>
</item>
<item>
<title>Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera</title>
<link>https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-and-takeda-present-longer-term-data-ash-2025-showing-rusfertide-delivers</link>
<guid isPermaLink="true">https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-and-takeda-present-longer-term-data-ash-2025-showing-rusfertide-delivers</guid>
<pubDate>Sat, 06 Dec 2025 05:00:00 GMT</pubDate>
<description>52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy</description>
</item>
<item>
<title>DELETED: Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice</title>
<link>https://6ix.com/company/protagonist-therapeutics-inc/news/deleted-protagenic-therapeutics-announces-receipt-nasdaq-non-compliance-notice-2025</link>
<guid isPermaLink="true">https://6ix.com/company/protagonist-therapeutics-inc/news/deleted-protagenic-therapeutics-announces-receipt-nasdaq-non-compliance-notice-2025</guid>
<pubDate>Thu, 27 Nov 2025 05:00:00 GMT</pubDate>
<description>This story has been deleted by the news</description>
</item>
<item>
<title>Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-reports-third-quarter-2025-financial-results-and-provides-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-reports-third-quarter-2025-financial-results-and-provides-corporate</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the</description>
</item>
<item>
<title>Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting</title>
<link>https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-therapeutics-announces-oral-and-poster-presentations-rusfertide-67th</link>
<guid isPermaLink="true">https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-therapeutics-announces-oral-and-poster-presentations-rusfertide-67th</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on</description>
</item>
<item>
<title>Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences</title>
<link>https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-announces-new-icotrokinra-data-ulcerative-colitis-and-plaque-psoriasis</link>
<guid isPermaLink="true">https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-announces-new-icotrokinra-data-ulcerative-colitis-and-plaque-psoriasis</guid>
<pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
<description>Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving</description>
</item>
<item>
<title>Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill</title>
<link>https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-announces-new-icotrokinra-data-ulcerative-colitis-showing-potential</link>
<guid isPermaLink="true">https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-announces-new-icotrokinra-data-ulcerative-colitis-showing-potential</guid>
<pubDate>Tue, 07 Oct 2025 04:00:00 GMT</pubDate>
<description>Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2%</description>
</item>
<item>
<title>Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress</title>
<link>https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-announces-presentations-clinical-data-120000241</link>
<guid isPermaLink="true">https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-announces-presentations-clinical-data-120000241</guid>
<pubDate>Wed, 17 Sep 2025 12:00:00 GMT</pubDate>
<description>Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed sustained skin clearance and favorable safety profile ...</description>
</item>
<item>
<title>Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress </title>
<link>https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-announces-presentations-clinical-data-icotrokinra-plaque-psoriasis-and</link>
<guid isPermaLink="true">https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-announces-presentations-clinical-data-icotrokinra-plaque-psoriasis-and</guid>
<pubDate>Wed, 17 Sep 2025 04:00:00 GMT</pubDate>
<description>Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3</description>
</item>
<item>
<title>Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025</title>
<link>https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-announces-icotrokinra-phase-2b-anthem-uc-trial-data-be-presented-united</link>
<guid isPermaLink="true">https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-announces-icotrokinra-phase-2b-anthem-uc-trial-data-be-presented-united</guid>
<pubDate>Mon, 15 Sep 2025 04:00:00 GMT</pubDate>
<description>NEWARK, CALIFORNIA / ACCESS Newswire / September 15, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that data from the Phase</description>
</item>
<item>
<title>Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency</title>
<link>https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-announces-icotrokinra-application-approval-plaque-psoriasis-submitted</link>
<guid isPermaLink="true">https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-announces-icotrokinra-application-approval-plaque-psoriasis-submitted</guid>
<pubDate>Thu, 11 Sep 2025 04:00:00 GMT</pubDate>
<description>Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1Filing based on four Phase 3 studies that</description>
</item>
<item>
<title>Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025</title>
<link>https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-therapeutics-participate-multiple-investment-bank-conferences-september</link>
<guid isPermaLink="true">https://6ix.com/company/protagonist-therapeutics-inc/news/protagonist-therapeutics-participate-multiple-investment-bank-conferences-september</guid>
<pubDate>Tue, 26 Aug 2025 04:00:00 GMT</pubDate>
<description>NEWARK, CALIFORNIA / ACCESS Newswire / August 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel,</description>
</item>
</channel>
</rss>